AstraZeneca buys CDK9 portfolio

AstraZeneca has purchased the CDK9 portfolio of Germany-based Probiodrug AG. The Halle, Germany, biotech announced the deal Thursday, but did not disclose the price tag.

The agreement means AstraZeneca will now own the lead drug and back-up compounds associated with the molecule, which has an impact on genetic transcription connected to inflammation, a condition which is associated with cancer and inflammatory diseases.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions